Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin consolidation with or without autologous stem cell transplantation in transformed non-Hodgkin lymphoma
NL-OMON39525Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jul 2010
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibritumomab tiuxetan in transformed B-cell lymphoma and mature B-cell lymphoma (2 arms), sponsored by Vrije University Medical Center. Primary endpoint: 2-year progression-free survival. Started Jul 2010; status: active, not recruiting.
02
Drugs
ibritumomab tiuxetan
03
Conditions
transformed B-cell lymphomamature B-cell lymphoma
Beyond the preview
Go deeper on NL-OMON39525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39525.